This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Whatling, C. Articles by Hurt-Camejo, E. Search for Related Content PubMed PubMed Citation Articles by Whatling, C. Articles by Hurt-Camejo, E.

(Arteriosclerosis, Thrombosis, and Vascular Biology. 2004;24:10.)
© 2004 American Heart Association, Inc.

Editorials

Matrix Management

Assigning Different Roles for MMP-2 and MMP-9 in Vascular Remodeling

Carl Whatling; William McPheat; Eva Hurt-Camejo

From AstraZeneca (C.W., W.M., E.H.-C.), R&D, Molecular Pharmacology, Mölndal; and Wallenberg Laboratory (E.H.-C.), Gothenburg University, Sahlgrenska Academy, Sweden.

Correspondence to Dr Eva Hurt-Camejo, Molecular Pharmacology, RA CV & GI, AstraZeneca, R&D, Mölndal, Sweden, S-431 83. E-mail eva.hurt-camejo@astrazeneca.com

An extract of the first 250 words of the full text is provided, because this article has no abstract.

Geometric remodeling is an important component of vascular pathologies, including restenosis and atherosclerosis. Although our understanding of the precise events involved in vascular remodeling is far from complete, it is generally accepted that local breakdown of extracellular matrix (ECM), smooth muscle cell migration, and matrix reorganization are important components.¹ In this respect, particular attention has been directed toward the role of matrix metalloproteinases (MMPs), enzymes capable of remodeling the ECM. However, being able to understand the specific contribution of individual members of a proteinase family that share overlapping substrates is a significant challenge.

See page 54

MMPs are Zn-containing neutral endopeptidases. At least 23 different MMPs have been identified that, as a family, have the capacity to degrade all components of the ECM, in addition to some nonmatrix substrates.² Within the family, several subgroups exist, based on substrate specificities or domain structures. The activity of MMPs is controlled at several distinct levels, including transcription, activation of zymogens, and interaction with specific inhibitors, the TIMPs (tissue inhibitors of MMPs). The two gelatinases MMP-2 and MMP-9 have received particular attention in analysis of vascular remodeling due to their expression by smooth muscle cells and leukocytes and ability to breakdown components of the basement membrane and collagens. At least in vitro, both enzymes have a very similar substrate profile. However, their expression in the vascular wall is differently controlled, in that a basal expression of MMP-2 can be detected within the media, whereas MMP-9 expression is only apparent after injury or inflammatory stimulation. . . . [Full Text of this Article]

This article has been cited by other articles:

				F. Mannello Serum or Plasma Samples?: The "Cinderella" Role of Blood Collection Procedures Preanalytical Methodological Issues Influence the Release and Activity of Circulating Matrix Metalloproteinases and Their Tissue Inhibitors, Hampering Diagnostic Trueness and Leading to Misinterpretation Arterioscler Thromb Vasc Biol, April 1, 2008; 28(4): 611 - 614. [Full Text] [PDF]

				U. Sen, N. Tyagi, M. Kumar, K. S. Moshal, W. E. Rodriguez, and S. C. Tyagi Cystathionine- -synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1779 - C1787. [Abstract] [Full Text] [PDF]

				P. K. Henke, C. G. Pearce, D. M. Moaveni, A. J. Moore, E. M. Lynch, C. Longo, M. Varma, N. A. Dewyer, K. B. Deatrick, G. R. Upchurch Jr, et al. Targeted Deletion of CCR2 Impairs Deep Vein Thombosis Resolution in a Mouse Model. J. Immunol., September 1, 2006; 177(5): 3388 - 3397. [Abstract] [Full Text] [PDF]

				D. Vigetti, P. Moretto, M. Viola, A. Genasetti, M. Rizzi, E. Karousou, F. Pallotti, G. De Luca, and A. Passi Matrix metalloproteinase 2 and tissue inhibitors of metalloproteinases regulate human aortic smooth muscle cell migration during in vitro aging FASEB J, June 1, 2006; 20(8): 1118 - 1130. [Abstract] [Full Text] [PDF]

				S. Janssens and H. R. Lijnen What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models? Cardiovasc Res, February 15, 2006; 69(3): 585 - 594. [Abstract] [Full Text] [PDF]

				J. Chen, C.-H. Tung, J. R. Allport, S. Chen, R. Weissleder, and P. L. Huang Near-Infrared Fluorescent Imaging of Matrix Metalloproteinase Activity After Myocardial Infarction Circulation, April 12, 2005; 111(14): 1800 - 1805. [Abstract] [Full Text] [PDF]

				P. K. Henke, A. Varga, S. De, C. B. Deatrick, J. Eliason, D. A. Arenberg, P. Sukheepod, P. Thanaporn, S. L. Kunkel, G. R. Upchurch Jr, et al. Deep Vein Thrombosis Resolution Is Modulated by Monocyte CXCR2-Mediated Activity in a Mouse Model Arterioscler Thromb Vasc Biol, June 1, 2004; 24(6): 1130 - 1137. [Abstract] [Full Text] [PDF]